STOCKHOLM, Sept. 16, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) invites to a conference call on the supporting clinical data from the completed dose escalation section of the phase 1b study with MIV-818, presented today at the European Society for Medical Oncology (ESMO)...